14ème JOURNEE DE L’INNOVATION
29 octobre 2020
Quatuor an effective drug combination to combat cancer Patrick Meraldi and Patrycja Nowak-Sliwinska
INTRODUCTION The Problem
- Over 8 million people worldwide die from cancer each year - Current cancer treatments induce severe side effects and drug resistance - NO EFFECTIVE CURE for metastasizing cancer
The options to outsmart cancer
- new targets; ideally shared in many cancer types and absent from healthy cells - innovative approaches: combination therapies to diminish side-effects and resistances
SOLUTION
Our Target: cancer cell divisions
Our Innovative Approach
chromosomes spindle poles
Quatuor
high efficacy
10 anti-cancer drugs at low doses
low toxicity
,)-$%&&%'( !"#!$%&&%'( ,)-$%&&%'( !"#!$%&&%'( ,)-$%&&%'( !"#!$%&&%'( ,)-$%&&%'( .%,%'("/"(+ .%,%'("/"(+ !"#!$()*"'"(+ !"#!$()*"'"(+ .%,%'("/"(+ !"#!$()*"'"(+ !"#!$()*"'"(+
(Erlotinib, Ci-944 Dasatanib, tubacin) cancer cell with multipolar spindle; present in up to 50% of all solid cancer cells
healthy cell
design of combinatorial matrix
testing for synergy
impairs division of cells with multipolar spindles
!
Advantages - no drug resistance due to a “low dose” - no side effects as healthy cells are unaffected - efficacy based on synergistic drug-drug interactions - works independently of tissue origin
CONCLUSION AND PERSPECTIVES Key future steps
screening for cell viability
Long-term benefits
Startup creation
Out-licensing Series B funding (searching) Series A funding (granted)
y over Disc
Lead ion izat optim
al Clinic ls Tria
al linic Prec ation lu a v e
Patient
Unmet medical need
Longer life expectancy Improved quality of life Reduced physical/ emotional pain
Improved efficacy (combinationapproach) Improved safety (lowering toxicity by low dosing) Clinical advancement
Pharma/ Biotech
Partners
Hospitals/ Insurances
Cash benefit
MDs
Cost savings by higher efficiency
Better treatment method Improved patient management Lowered risk of malpractice Time-saving
UNIGE today
Testing our drug combination in animal models
FACULTE DE MEDECINE FACULTE DES SCIENCES
CENTRE DE RECHERCHE TRANSLATIONELLE D’ONCOHEMATOLOGIE
